✦ LIBER ✦

Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay

✍ Scribed by L. Chemello; P. Pontisso; G. Fattovich; E. Schiavon; Dr. A. Alberti; G. Realdi

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 379 KB
Volume: 17
Category: Article
ISSN: 0146-6615
DOI: 10.1002/jmv.1890170108

No coin nor oath required. For personal study only.

✦ Synopsis

Serum hepatitis B core antigen (HBcAg) was investigated in 85 patients with chronic hepatitis B virus (HBV) infection using a modified radioimmunoassay technique, based on high molarity treatment of samples to avoid masking of the antigen by the excess homologous antibody. Eighty-eight percent of HBeAg-positive cases and 19% of anti-HBe-positive cases were HBcAg positive in serum, with a positive correlation with the presence of HBcAg in the liver. Although the sensitivity of the method for the presence of complete virions was not absolute, as shown by the comparison with serum HBV-DNA testing, this technique may be helpful for assessing virus synthesis in patients with HBV infection.

📜 SIMILAR VOLUMES

Correlation of serum hepatitis B surface

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B

✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Correlation between serum hepatitis B vi

Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

✍ Fumitaka Suzuki; Hideo Miyakoshi; Mariko Kobayashi; Hiromitsu Kumada 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

## Abstract Nucleos(t)ide analogues are utilized for the treatment of chronic HBV infection, and HBe seroconversion and HBV DNA levels are commonly used as markers of viral status and as primary treatment endpoints. Recently, a new assay was prepared for the detection of serum HBV core‐related anti

Clinical utility of hepatitis B surface

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review

✍ Yun-Fan Liaw 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin

Clinical utility of hepatitis B surface

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review

✍ Yun-Fan Liaw 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

Characterization of viral kinetics in pa

Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B

✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60